JanOne Inc. (JAN) Stock

JanOne Inc. (JAN) is a Real Estate stock trading at $30.72 (as of 2026-08-21), with a market capitalization of $8.33B and a trailing P/E of 245.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

JanOne Inc. is a clinical-stage biopharmaceutical and technology company that focuses on developing and partnering for non-opioid therapies, along with operating recycling and wireless technologies. Its segments include Biotechnology, Recycling, and Technology, including the JAN101 sodium nitrite oral sustained-release candidate for pain in people with diabetes or peripheral artery disease.

Understand JanOne Inc.: how it makes money

JanOne Inc. develops, licenses, and commercializes novel non-opioid and non-addictive therapies to address pain and addiction, including JAN101, an oral sustained release sodium nitrite formulation targeting poor blood flow to the extremities in diabetes or peripheral artery disease.

Profit performance appears to be driven by turning acquisition activity into completed senior housing deals, maintaining joint venture portfolio occupancy, and generating cash from non-refundable entrance fee sales.

Business quality (Mixed): Information quality is mixed, the narrative describes a clinical-stage biopharmaceutical company, while the provided operating KPIs focus on senior housing acquisitions, entrance fees, and joint venture occupancy. This makes it harder to confidently connect the stated business to the operating drivers.

Bull case

  • Targeted therapy concept (JAN101): The lead product candidate JAN101 is a patented oral and sustained release composition of sodium nitrite intended to target poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain.
  • Execution signals from operating KPIs: In the latest reported set of operating KPIs, senior housing acquisitions completed were 4183 units with a reported completed acquisition value of 0.71 USD_B, and joint venture portfolio occupancy was 80%.

Bear case

  • Clinical-stage and commercialization uncertainty: The company is described as clinical-stage, so outcomes of development and the ability to commercialize therapies remain uncertain.
  • Growth dependence on continued deal flow and demand: The operating KPIs show that incremental senior housing acquisitions under contract and non-refundable entrance fee sales are meaningful inputs, so weaker deal flow or weaker entrance fee demand could pressure results.
Valuation — source: SEC EDGAR (first-party)
Price$30.72
Market Cap$8.33B
P/E Ratio245.5
EV / EBITDA31.6
Price / Book2.25
Price / Sales11.65
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$603.99M
Net Margin1.1%
Revenue Growth (YoY)45.4%
Valuation vs Sector & Industry
Stock P/E245.5
Sector P/E (Real Estate)27.2
Industry P/E (Trading)35.3
vs Sector803.4%
vs Industry594.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($59.21M)
Institutional Holders Tracked2
Company
SectorReal Estate
IndustryTrading
CEOTony Isaac
Employees5
CountryUS
IPO Date1991-11-07

Related Companies (Business model: Equity REIT (Real Estate Investment Trust); 8 closest by market cap; US-domiciled)

  • Alexandria Real Estate Equities, Inc. (ARE)
  • CubeSmart (CUBE)
  • Brixmor Property Group Inc. (BRX)
  • Agree Realty Corporation (ADC)
  • NNN REIT, Inc. (NNN)
  • First Industrial Realty Trust, Inc. (FR)
  • Rexford Industrial Realty, Inc. (REXR)
  • Ryman Hospitality Properties, Inc. (RHP)
JAN earnings history · JAN institutional & insider holders · JAN KPIs & operating metrics · JAN financials · JAN investor presentations & press releases · JAN SEC filings · JAN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.